Logo image of TRAW

TRAWS PHARMA INC (TRAW) Stock Fundamental Analysis

NASDAQ:TRAW - Nasdaq - US68232V8845 - Common Stock - Currency: USD

7.81  +0.14 (+1.83%)

After market: 8.16 +0.35 (+4.48%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TRAW. TRAW was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TRAW have multiple concerns. TRAW does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TRAW has reported negative net income.
In the past year TRAW has reported a negative cash flow from operations.
In the past 5 years TRAW always reported negative net income.
TRAW had a negative operating cash flow in each of the past 5 years.
TRAW Yearly Net Income VS EBIT VS OCF VS FCFTRAW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

TRAW has a Return On Assets of -1575.48%. This is amonst the worse of the industry: TRAW underperforms 97.85% of its industry peers.
Industry RankSector Rank
ROA -1575.48%
ROE N/A
ROIC N/A
ROA(3y)-53.61%
ROA(5y)N/A
ROE(3y)-93.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRAW Yearly ROA, ROE, ROICTRAW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -50 -100 -150

1.3 Margins

TRAW does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRAW Yearly Profit, Operating, Gross MarginsTRAW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

TRAW does not have a ROIC to compare to the WACC, probably because it is not profitable.
TRAW has more shares outstanding than it did 1 year ago.
TRAW has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRAW Yearly Shares OutstandingTRAW Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 200K 400K 600K 800K
TRAW Yearly Total Debt VS Total AssetsTRAW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

TRAW has an Altman-Z score of -104.54. This is a bad value and indicates that TRAW is not financially healthy and even has some risk of bankruptcy.
TRAW has a worse Altman-Z score (-104.54) than 94.62% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -104.54
ROIC/WACCN/A
WACC9.57%
TRAW Yearly LT Debt VS Equity VS FCFTRAW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M

2.3 Liquidity

A Current Ratio of 1.07 indicates that TRAW should not have too much problems paying its short term obligations.
TRAW has a worse Current ratio (1.07) than 84.41% of its industry peers.
A Quick Ratio of 1.07 indicates that TRAW should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.07, TRAW is not doing good in the industry: 77.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 1.07
TRAW Yearly Current Assets VS Current LiabilitesTRAW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

TRAW shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.10%.
Looking at the last year, TRAW shows a decrease in Revenue. The Revenue has decreased by 0.00% in the last year.
EPS 1Y (TTM)1.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3730.43%
Revenue 1Y (TTM)0%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0%

3.2 Future

Based on estimates for the next years, TRAW will show a small growth in Earnings Per Share. The EPS will grow by 2.66% on average per year.
The Revenue is expected to grow by 11.69% on average over the next years. This is quite good.
EPS Next Y-17393%
EPS Next 2Y-534.48%
EPS Next 3Y2.66%
EPS Next 5YN/A
Revenue Next Year6.81%
Revenue Next 2Y3.35%
Revenue Next 3Y11.69%
Revenue Next 5YN/A

3.3 Evolution

TRAW Yearly Revenue VS EstimatesTRAW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
TRAW Yearly EPS VS EstimatesTRAW Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50K -100K -150K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TRAW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TRAW is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRAW Price Earnings VS Forward Price EarningsTRAW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRAW Per share dataTRAW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-534.48%
EPS Next 3Y2.66%

More info and screens

0

5. Dividend

5.1 Amount

TRAW does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRAWS PHARMA INC

NASDAQ:TRAW (2/5/2025, 8:00:01 PM)

After market: 8.16 +0.35 (+4.48%)

7.81

+0.14 (+1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners100.68%
Inst Owner Change0%
Ins Owners27.01%
Ins Owner Change0%
Market Cap23.66M
Analysts82.86
Price Target153 (1859.03%)
Short Float %8.11%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.26%
Min Revenue beat(2)-6.86%
Max Revenue beat(2)-3.65%
Revenue beat(4)0
Avg Revenue beat(4)-8.74%
Min Revenue beat(4)-15.96%
Max Revenue beat(4)-3.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.69%
EPS NQ rev (1m)-36.43%
EPS NQ rev (3m)-3193.1%
EPS NY rev (1m)0%
EPS NY rev (3m)-2607.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 104.71
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-36.23
Fwd EYN/A
FCF(TTM)-9.96
FCFYN/A
OCF(TTM)-9.96
OCFYN/A
SpS0.07
BVpS-0.67
TBVpS-0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1575.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.61%
ROA(5y)N/A
ROE(3y)-93.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 1.07
Altman-Z -104.54
F-Score3
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3730.43%
EPS Next Y-17393%
EPS Next 2Y-534.48%
EPS Next 3Y2.66%
EPS Next 5YN/A
Revenue 1Y (TTM)0%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next Year6.81%
Revenue Next 2Y3.35%
Revenue Next 3Y11.69%
Revenue Next 5YN/A
EBIT growth 1Y-3.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.72%
EBIT Next 3Y-16.08%
EBIT Next 5YN/A
FCF growth 1Y-10.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.05%
OCF growth 3YN/A
OCF growth 5YN/A